目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Indication
1.2.2. Route of Administration
1.2.3. Vector Type
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of cancer
3.2.1.2. Advancements in gene therapy technology
3.2.1.3. Increasing adopton of personalized medicine
3.2.2. Market Restraint Analysis
3.2.2.1. High costs of treatment
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis
4.1. Indication Segment Dashboard
4.2. Global Cancer Gene Therapy Market Indication, Movement Analysis
4.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
4.4. Large B-Cell Lymphoma
4.4.1. Global Large B-Cell Lymphoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Multiple Myeloma
4.5.1. Global Multiple Myeloma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Acute Lymphoblastic Leukemia (ALL)
4.6.1. Global Acute Lymphoblastic Leukemia (ALL) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Melanoma (lesions)
4.7.1. Global Melanoma (lesions) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis
5.1. Route of Administration Segment Dashboard
5.2. Global Cancer Gene Therapy Market Route of Administration Movement Analysis
5.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Intravenous
5.4.1. Global Intravenous Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis
6.1. Vector Type Segment Dashboard
6.2. Global Cancer Gene Therapy Market Vector Type Movement Analysis
6.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
6.4. Lentivirus
6.4.1. Global Lentivirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. RetroVirus & gamma RetroVirus
6.5.1. Global RetroVirus & gamma RetroVirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. AAV
6.6.1. Global AAV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Modified Herpes Simplex Virus
6.7.1. Global Modified Herpes Simplex Virus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Adenovirus
6.8.1. Global Adenovirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Others
6.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. Mexico
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. Mexico Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Switzerland
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. France Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. China
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. South Korea
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. South Korea Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Rest of the World
7.6.1. Rest of the World Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Participant’s Overview
8.4.1. Amgen Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Gilead Sciences, Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. bluebird bio, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Bristol-Myers Squibb Company
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Legend Biotech.
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Nanjing IASO Biotechnology
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. JW Therapeutics
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. CARsgen Therapeutics
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Krystal Biotech, Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 4 Global cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 5 Global cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 6 Global cancer gene therapy market, by region, 2018 - 2030 (USD Million)
Table 7 North America cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 8 North America cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 9 North America cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 10 North America cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 11 U.S. cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 12 U.S. cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 13 U.S. cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 14 Canada cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 15 Canada cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 16 Canada cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 17 Mexico cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 18 Mexico cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 19 Mexico cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 20 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 21 Europe cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 22 Europe cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 23 Europe cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 24 UK cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 25 UK cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 26 UK cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 27 Germany cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 28 Germany cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 29 Germany cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 30 Switzerland cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 31 Switzerland cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 32 Switzerland cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 33 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 35 Asia Pacific cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 36 Asia Pacific cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 37 Japan cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 38 Japan cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 39 Japan cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 40 China cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 41 China cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 42 China cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 43 South Korea cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 44 South Korea cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 45 South Korea cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 46 Rest of the world cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 47 Rest of the world cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 48 Rest of the world cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 49 Participant's overview
Table 50 Financial performance
Table 51 Key companies undergoing expansions
Table 52 Key companies undergoing acquisitions
Table 53 Key companies undergoing collaborations
Table 54 Key companies launching new products
Table 55 Key companies undertaking other strategies

List of Figures
Fig. 1 Cancer gene therapy market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Market outlook
Fig. 8 Segment snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook
Fig. 11 Cancer gene therapy market driver analysis
Fig. 12 Cancer gene therapy market restraint analysis
Fig. 13 Cancer gene therapy market: Porter's analysis
Fig. 14 Cancer gene therapy market: PESTEL analysis
Fig. 15 Cancer gene therapy market: Indication outlook and key takeaways
Fig. 16 Cancer gene therapy market: Indication market share analysis, 2024 - 2030
Fig. 17 Global cancer gene therapy by large B-cell lymphoma market, 2018 - 2030 (USD Million)
Fig. 18 Global cancer gene therapy by multiple myeloma market, 2018 - 2030 (USD Million)
Fig. 19 Global cancer gene therapy by Acute Lymphoblastic Leukemia (ALL) market, 2018 - 2030 (USD Million)
Fig. 20 Global cancer gene therapy by melanoma (lesions) market, 2018 - 2030 (USD Million)
Fig. 21 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 22 Cancer gene therapy market: Route of administration outlook and key takeaways
Fig. 23 Cancer gene therapy market: Route of administration market share analysis, 2024 - 2030
Fig. 24 Global cancer gene therapy by intravenous market, 2018 - 2030 (USD Million)
Fig. 25 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 26 Cancer gene therapy market: Vector type outlook and key takeaways
Fig. 27 Cancer gene therapy market: Vector type market share analysis, 2024 - 2030
Fig. 28 Global cancer gene therapy by lentivirus market, 2018 - 2030 (USD Million)
Fig. 29 Global cancer gene therapy by retrovirus & gamma retrovirus market, 2018 - 2030 (USD Million)
Fig. 30 Global cancer gene therapy by AAV market, 2018 - 2030 (USD Million)
Fig. 31 Global cancer gene therapy by modified herpes simplex virus market, 2018 - 2030 (USD Million)
Fig. 32 Global cancer gene therapy by adenovirus market, 2018 - 2030 (USD Million)
Fig. 33 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S. cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Canada cancer gene therapy market, 2018 - 2030 (USD Million)
Fig. 38 Mexico cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 UK cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Switzerland cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Asia-Pacific cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Japan cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 China cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 South Korea cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Rest of the world cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Key company categorization
Fig. 49 Company market positioning
Fig. 50 Market participant categorization
Fig. 51 Strategy framework